Kenvue Inc. $KVUE Shares Bought by Saudi Central Bank

Saudi Central Bank boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 89.7% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 134,172 shares of the company’s stock after purchasing an additional 63,450 shares during the quarter. Saudi Central Bank’s holdings in Kenvue were worth $2,564,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Elyxium Wealth LLC acquired a new stake in shares of Kenvue in the fourth quarter worth $26,000. Johnson Financial Group Inc. purchased a new position in shares of Kenvue during the second quarter worth $26,000. MV Capital Management Inc. acquired a new position in Kenvue during the fourth quarter valued at $28,000. CoreCap Advisors LLC lifted its position in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares during the period. Finally, Reflection Asset Management purchased a new stake in Kenvue in the fourth quarter valued at $32,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE stock opened at $18.70 on Tuesday. The company has a market capitalization of $35.92 billion, a P/E ratio of 21.49, a P/E/G ratio of 1.67 and a beta of 0.46. The business’s 50 day moving average is $19.18 and its two-hundred day moving average is $18.26. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $20.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th were paid a $0.21 dividend. The ex-dividend date of this dividend was Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a yield of 4.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is 96.55%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several analyst reports. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. UBS Group dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Barclays lifted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.